冨田 章裕

Medicine & Life Sciences

1. Myelodysplastic Syndromes 100%
2. Rituximab 96%
3. Lymphoma 88%
4. B-Cell Lymphoma 88%
5. Acute Myeloid Leukemia 53%
6. Mutation 48%
7. Lymphoma, Large B-Cell, Diffuse 47%
8. Leukemia 44%
9. Thyroid Hormone Receptors 43%
10. Co-Repressor Proteins 42%
11. DNA 39%
12. Cell-Free Nucleic Acids 38%
13. Japan 36%
14. Thyroid Hormones 35%
15. Proteins 33%
16. Genes 33%
17. Acetylation 33%
18. Neoplasms 29%
19. Hodgkin Disease 28%
20. Acute Promyelocytic Leukemia 28%
21. Hematology 28%
22. T-Lymphocytes 27%
23. Survival 27%
24. Multicenter Studies 26%
25. Azacitidine 24%
26. Histones 24%
27. pembrolizumab 24%
28. Apoptosis 24%
29. Retrospective Studies 24%
30. Therapeutics 24%
31. Hemosiderin 23%
32. Methylation 23%
33. Arsenic Trioxide 23%
34. Bortezomib 23%
35. B-Lymphocytes 22%
36. Anura 22%
37. Epigenomics 22%
38. Lymphoproliferative Disorders 21%
39. Safety 21%
40. Myeloid Cells 20%
41. Hematopoietic Stem Cell Transplantation 19%
42. Messenger RNA 19%
43. ravulizumab 19%
44. Human Herpesvirus 4 19%
45. asciminib 18%
46. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18%
47. Bone Marrow 18%
48. Ferritins 18%
49. Chromatin 18%
50. Drug Therapy 17%